Home Tags SLC39A6

Tag: SLC39A6

BioRay’s IND Application for BRY812, Accepted by the China National Medical...

The China National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for BRY812, a novel antibody-drug conjugate (ADC) targeting human LIV-1 for the treatment of advanced malignant tumors (Acceptance No. CXSL2300366).  The investigational drug is being developed by Shanghai-based BioRay Pharmaceutical Co.

Phase I Trial of SGN-LIV1A Initiated in LIV-1-Positive Metastatic Breast Cancer

A new phase I clinical trial was initiated late October 2013 to evaluate SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer. SGN-LIV1A is based...

X